Clinical efficacy of urethral balloon dilation in patients with spinal cord injury-induced neurogenic bladder
尿道球囊扩张术在脊髓损伤神经源性膀胱患者中的应用效果

摘要

目的 揭示对脊髓损伤神经源性膀胱患者尿道球囊扩张术治疗处置的临床价值。方法 2024年2月-2025年8月，将88例脊髓损伤神经源性膀胱患者随机分两组，各44例，参照组低频电子脉冲治疗处置，研究组尿道球囊扩张术治疗处置，测算比照两组的治疗结果满意度测算数据值、治疗后自行排尿实现率测算数据值，以及接受治疗前后的症状自评量表（SCL-90）评分测算数据值。结果 研究组的治疗结果满意度测算数据值高于参照组（P<0.05）。研究组的治疗后自行排尿实现率测算数据值高于参照组（P<0.05）。治疗前，研究组的SCL-90评分测算数据值与参照组大致相当（P>0.05）。治疗后，研究组的SCL-90评分测算数据值优于参照组（P<0.05）。结论 对脊髓损伤神经源性膀胱患者尿道球囊扩张术治疗处置，价值充分，值得推广。

Abstract

Objective To elucidate the clinical value of urethral balloon dilation in the treatment of spinal cord injury-induced neurogenic bladder.
Methods From February 2024 to August 2025, 88 patients with spinal cord injury and neurogenic bladder were randomly divided into two groups, with 44 patients in each group. The control group received low-frequency electronic pulse therapy, while the study group underwent urethral balloon dilation therapy. The satisfaction scores, the achievement rate of spontaneous urination after treatment, and the SCL-90 scores before and after treatment were calculated and compared between the two groups.
Results The satisfaction measurement data value of the treatment group was higher than that of the control group (P<0.05). The achievement rate measurement data value of spontaneous urination after treatment in the treatment group was higher than that in the control group (P<0.05). Before treatment, the Symptom Checklist‑90 (SCL-90) score measurement data value of the treatment group was roughly equivalent to that of the control group (P>0.05). After treatment, the SCL-90 score measurement data value of the treatment group was superior to that of the control group (P<0.05).
Conclusion   Urethral balloon dilation demonstrates significant clinical value in the treatment of spinal cord injury-induced neurogenic bladder and is worthy of widespread adoption.